Prognostic impact of bleomycin pulmonary toxicity on the outcomes of patients with germ cell tumors

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Bleomycin pulmonary toxicity (BPT) has been well described in patients with germ cell tumors treated with bleomycin etoposide and cisplatin chemotherapy (BEP). To assess the prognostic impact of BPT, we retrospectively identified 52 patients who underwent bleomycin etoposide and cisplatin chemotherapy from 2008 to 2017 in our institution, and evaluated the risk factors of BPT and its effect on prognosis. Patients who had received chemotherapy at another institution were excluded. BPT was defined as bleomycin discontinuation in response to pulmonary function test decline, pulmonary symptoms, or interstitial pneumonia on computed tomography without infection. We divided the patients into two groups according to this definition: BPT and non-BPT. Their median age was 34.2 years, and their median body mass index was 22.8 kg/m2. Twenty patients had a smoking history, 37 were diagnosed with non-seminoma, and 20 had lung metastasis. The median cumulative bleomycin dose was 270 mg/body. Fifteen patients were classified into the BPT group and 37 into the non-BPT group. Only body mass index < 22 was identified as a predictor of BPT in multivariable logistic models. Age or use of granulocyte-colony stimulating factor did not have a significant impact. Kaplan–Meier analysis revealed that the presence of BPT had no significant impact on either 5-year overall survival or progression-free survival. Lower body mass index can increase the risk of BPT in patients with germ cell tumors undergoing BEP. However, discontinuation of bleomycin with BPT does not adversely influence the survival outcomes.

Original languageEnglish
Article number80
JournalMedical Oncology
Volume35
Issue number6
DOIs
Publication statusPublished - Jun 1 2018

Fingerprint

Germ Cell and Embryonal Neoplasms
Bleomycin
Lung
Body Mass Index
Etoposide
Drug Therapy
Cisplatin
Survival
Respiratory Function Tests
Interstitial Lung Diseases
Granulocyte Colony-Stimulating Factor
Disease-Free Survival

Keywords

  • Bleomycin
  • Germ cell tumor
  • Pulmonary toxicity
  • Testicular cancer

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

@article{3adef1904d5d426cb761af70124c96cb,
title = "Prognostic impact of bleomycin pulmonary toxicity on the outcomes of patients with germ cell tumors",
abstract = "Bleomycin pulmonary toxicity (BPT) has been well described in patients with germ cell tumors treated with bleomycin etoposide and cisplatin chemotherapy (BEP). To assess the prognostic impact of BPT, we retrospectively identified 52 patients who underwent bleomycin etoposide and cisplatin chemotherapy from 2008 to 2017 in our institution, and evaluated the risk factors of BPT and its effect on prognosis. Patients who had received chemotherapy at another institution were excluded. BPT was defined as bleomycin discontinuation in response to pulmonary function test decline, pulmonary symptoms, or interstitial pneumonia on computed tomography without infection. We divided the patients into two groups according to this definition: BPT and non-BPT. Their median age was 34.2 years, and their median body mass index was 22.8 kg/m2. Twenty patients had a smoking history, 37 were diagnosed with non-seminoma, and 20 had lung metastasis. The median cumulative bleomycin dose was 270 mg/body. Fifteen patients were classified into the BPT group and 37 into the non-BPT group. Only body mass index < 22 was identified as a predictor of BPT in multivariable logistic models. Age or use of granulocyte-colony stimulating factor did not have a significant impact. Kaplan–Meier analysis revealed that the presence of BPT had no significant impact on either 5-year overall survival or progression-free survival. Lower body mass index can increase the risk of BPT in patients with germ cell tumors undergoing BEP. However, discontinuation of bleomycin with BPT does not adversely influence the survival outcomes.",
keywords = "Bleomycin, Germ cell tumor, Pulmonary toxicity, Testicular cancer",
author = "Yuki Maruyama and Takuya Sadahira and Yosuke Mitsui and Motoo Araki and Koichiro Wada and Ryuta Tanimoto and Yasuyuki Kobayashi and Masami Watanabe and Toyohiko Watanabe and Yasutomo Nasu",
year = "2018",
month = "6",
day = "1",
doi = "10.1007/s12032-018-1140-5",
language = "English",
volume = "35",
journal = "Medical Oncology",
issn = "1357-0560",
publisher = "Humana Press",
number = "6",

}

TY - JOUR

T1 - Prognostic impact of bleomycin pulmonary toxicity on the outcomes of patients with germ cell tumors

AU - Maruyama, Yuki

AU - Sadahira, Takuya

AU - Mitsui, Yosuke

AU - Araki, Motoo

AU - Wada, Koichiro

AU - Tanimoto, Ryuta

AU - Kobayashi, Yasuyuki

AU - Watanabe, Masami

AU - Watanabe, Toyohiko

AU - Nasu, Yasutomo

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Bleomycin pulmonary toxicity (BPT) has been well described in patients with germ cell tumors treated with bleomycin etoposide and cisplatin chemotherapy (BEP). To assess the prognostic impact of BPT, we retrospectively identified 52 patients who underwent bleomycin etoposide and cisplatin chemotherapy from 2008 to 2017 in our institution, and evaluated the risk factors of BPT and its effect on prognosis. Patients who had received chemotherapy at another institution were excluded. BPT was defined as bleomycin discontinuation in response to pulmonary function test decline, pulmonary symptoms, or interstitial pneumonia on computed tomography without infection. We divided the patients into two groups according to this definition: BPT and non-BPT. Their median age was 34.2 years, and their median body mass index was 22.8 kg/m2. Twenty patients had a smoking history, 37 were diagnosed with non-seminoma, and 20 had lung metastasis. The median cumulative bleomycin dose was 270 mg/body. Fifteen patients were classified into the BPT group and 37 into the non-BPT group. Only body mass index < 22 was identified as a predictor of BPT in multivariable logistic models. Age or use of granulocyte-colony stimulating factor did not have a significant impact. Kaplan–Meier analysis revealed that the presence of BPT had no significant impact on either 5-year overall survival or progression-free survival. Lower body mass index can increase the risk of BPT in patients with germ cell tumors undergoing BEP. However, discontinuation of bleomycin with BPT does not adversely influence the survival outcomes.

AB - Bleomycin pulmonary toxicity (BPT) has been well described in patients with germ cell tumors treated with bleomycin etoposide and cisplatin chemotherapy (BEP). To assess the prognostic impact of BPT, we retrospectively identified 52 patients who underwent bleomycin etoposide and cisplatin chemotherapy from 2008 to 2017 in our institution, and evaluated the risk factors of BPT and its effect on prognosis. Patients who had received chemotherapy at another institution were excluded. BPT was defined as bleomycin discontinuation in response to pulmonary function test decline, pulmonary symptoms, or interstitial pneumonia on computed tomography without infection. We divided the patients into two groups according to this definition: BPT and non-BPT. Their median age was 34.2 years, and their median body mass index was 22.8 kg/m2. Twenty patients had a smoking history, 37 were diagnosed with non-seminoma, and 20 had lung metastasis. The median cumulative bleomycin dose was 270 mg/body. Fifteen patients were classified into the BPT group and 37 into the non-BPT group. Only body mass index < 22 was identified as a predictor of BPT in multivariable logistic models. Age or use of granulocyte-colony stimulating factor did not have a significant impact. Kaplan–Meier analysis revealed that the presence of BPT had no significant impact on either 5-year overall survival or progression-free survival. Lower body mass index can increase the risk of BPT in patients with germ cell tumors undergoing BEP. However, discontinuation of bleomycin with BPT does not adversely influence the survival outcomes.

KW - Bleomycin

KW - Germ cell tumor

KW - Pulmonary toxicity

KW - Testicular cancer

UR - http://www.scopus.com/inward/record.url?scp=85046300935&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046300935&partnerID=8YFLogxK

U2 - 10.1007/s12032-018-1140-5

DO - 10.1007/s12032-018-1140-5

M3 - Article

VL - 35

JO - Medical Oncology

JF - Medical Oncology

SN - 1357-0560

IS - 6

M1 - 80

ER -